Semaglutide — Research Peptide Overview, Specifications, and Sourcing

At-a-Glance Specifications

CAS Number

910463-68-2

Molecular Weight

4113.58 g/mol

Molecular Formula

C₁₈₇H₂₉₁N₄₅O₅₉

Amino Acid Sequence

Modified GLP-1(7-37) analog: His-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys(C18 fatty diacid via linker)-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly

Purity

≥99% (HPLC verified)

Physical Form

Lyophilized powder

Storage

-20°C lyophilized; 2-8°C reconstituted

Synonyms

Ozempic (brand), Wegovy (brand), NN9535

What Is Semaglutide?

Semaglutide is a long-acting glucagon-like peptide-1 receptor agonist (GLP-1 RA) that was developed as a structural analog of human GLP-1(7-37). The peptide incorporates several key modifications to the native GLP-1 sequence that dramatically enhance its pharmacokinetic profile: an alpha-aminoisobutyric acid (Aib) substitution at position 8 confers resistance to dipeptidyl peptidase-4 (DPP-4) cleavage, while a C18 fatty diacid chain attached to lysine at position 26 via a linker enables strong, non-covalent binding to serum albumin. These modifications extend the circulating half-life from the approximately 2-minute half-life of native GLP-1 to approximately 165 hours (~7 days), enabling once-weekly dosing in clinical research.

First described in the scientific literature by Lau et al. (2015), semaglutide represents a second-generation GLP-1 receptor agonist with improved pharmacokinetic properties compared to earlier analogs such as liraglutide. The compound has become one of the most intensively studied peptides in metabolic research, with a vast body of clinical and preclinical data examining its effects on glycemic control, body weight regulation, cardiovascular outcomes, and emerging areas including neurological and hepatic research.

From a structural perspective, semaglutide shares 94% homology with native human GLP-1(7-37), with only three amino acid modifications. Despite these minimal structural changes, the pharmacokinetic and pharmacodynamic properties differ substantially from the native hormone, providing sustained receptor activation over an extended time period. This sustained signaling profile has been associated with robust effects on appetite regulation, gastric emptying, and insulin secretion in research models.

For wholesale research suppliers, semaglutide has emerged as a critically important catalog compound due to the explosive growth in GLP-1-related research. Demand from academic institutions, pharmaceutical companies, contract research organizations, and independent laboratories continues to accelerate as the scope of GLP-1 receptor agonist research expands into new therapeutic areas.

Mechanism of Action

Semaglutide exerts its biological effects primarily through activation of the GLP-1 receptor, a G protein-coupled receptor (GPCR) expressed across multiple organ systems. Its mechanism involves several interconnected physiological pathways.

GLP-1 Receptor Activation

Semaglutide binds to and activates the GLP-1 receptor with high affinity, triggering intracellular signaling cascades including cAMP/PKA and PI3K/Akt pathways. Lau et al. (2015) demonstrated that semaglutide exhibited comparable in vitro potency to native GLP-1 at the GLP-1 receptor while achieving vastly superior in vivo efficacy due to its extended pharmacokinetic profile (PMID: 25648656).

Glucose-Dependent Insulin Secretion

Through GLP-1 receptor activation on pancreatic beta cells, semaglutide enhances glucose-dependent insulin secretion. This glucose-dependent mechanism means that insulin release is potentiated only when blood glucose levels are elevated, reducing the risk of hypoglycemia compared to agents that stimulate insulin release regardless of glucose levels. Additionally, semaglutide suppresses glucagon secretion from alpha cells in a glucose-dependent manner.

Appetite and Food Intake Regulation

Semaglutide modulates appetite through both central and peripheral mechanisms. In the central nervous system, the peptide acts on GLP-1 receptors in the hypothalamus and brainstem to reduce hunger signaling and increase satiety. Peripherally, it delays gastric emptying, prolonging the feeling of fullness after food intake. Blundell et al. (2017) demonstrated that semaglutide reduced appetite and ad libitum energy intake in research subjects, with associated reductions in food cravings and preference for high-fat foods (PMID: 28655529).

Cardiovascular Mechanisms

Research has identified direct cardiovascular effects of semaglutide mediated through GLP-1 receptors expressed on cardiomyocytes, endothelial cells, and vascular smooth muscle cells. These effects include anti-inflammatory actions, reduction of oxidative stress, and improvements in endothelial function. Marso et al. (2016) published the landmark SUSTAIN-6 trial demonstrating cardiovascular outcome benefits associated with semaglutide treatment in a clinical trial setting (PMID: 27633186).

Neuroprotective Mechanisms

Emerging research has identified potential neuroprotective effects of semaglutide mediated through brain-expressed GLP-1 receptors. These mechanisms include anti-inflammatory effects in the central nervous system, improved neuronal insulin signaling, and reduced amyloid-beta pathology in preclinical Alzheimer’s disease models.

Research Applications

Metabolic and Obesity Research

Semaglutide is one of the most extensively studied compounds in metabolic research. Preclinical and clinical investigations have examined its effects on body weight regulation, insulin sensitivity, lipid metabolism, and metabolic syndrome components. The compound’s robust effects on appetite regulation and energy balance have made it a reference standard in obesity research.

Diabetes and Glycemic Control Research

The SUSTAIN clinical trial program (SUSTAIN 1-10) generated extensive data on semaglutide’s glycemic effects, establishing it as a benchmark compound for GLP-1 receptor agonist research. Preclinical studies continue to explore its mechanisms of beta-cell preservation, glucagon regulation, and hepatic glucose output modulation.

Cardiovascular Research

Following the SUSTAIN-6 and SELECT trials, semaglutide has become a key compound in cardiovascular research exploring the cardiometabolic benefits of GLP-1 receptor activation. Areas of investigation include atherosclerosis, heart failure, and vascular inflammation.

Neuroscience Research

A growing body of research is examining semaglutide in neurological disease models, including Alzheimer’s disease, Parkinson’s disease, and stroke. GLP-1 receptors are expressed throughout the brain, and semaglutide’s ability to cross the blood-brain barrier has generated interest in its neurological research applications.

Hepatic Research

Semaglutide is under investigation in models of non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD). Research has demonstrated effects on hepatic lipid metabolism, liver inflammation, and fibrosis in preclinical and clinical settings.

Available Formats and Bulk Options

• Standard Research Vials: 3 mg and 5 mg lyophilized powder per vial
• High-Volume Vials: 10 mg lyophilized powder per vial
• Bulk Lyophilized Powder: Available in 100 mg, 500 mg, and 1 g quantities
• Custom Formulations: Available upon request for specific research protocols

All formats include batch-specific certificates of analysis with full analytical documentation.

Wholesale Pricing Summary

For detailed pricing and custom quotes, visit our wholesale pricing page or contact our B2B sales team.

Quality, Testing, and Certificates of Analysis

• HPLC Purity Analysis: Reverse-phase HPLC confirms peptide purity ≥99%.
• Mass Spectrometry: ESI-MS or MALDI-TOF-MS verifies the expected molecular weight of 4113.58 g/mol and confirms the fatty acid modification.
• Amino Acid Analysis: Confirms correct sequence composition including the Aib substitution at position 8.
• Endotoxin Testing: LAL assay ensures levels <1 EU/mg.
• Sterility Testing: Per USP standards for in vivo-grade presentations.
• Fatty Acid Conjugation Verification: LC-MS analysis confirms proper C18 fatty diacid attachment at the Lys26 position.

Storage and Stability

Lyophilized Form

• Long-term storage: -20°C or below, protected from light. Shelf life of 24+ months.
• Short-term storage: 2-8°C for up to 4 weeks.

Reconstituted Solution

• Recommended vehicle: Bacteriostatic water or sterile phosphate-buffered saline (PBS).
• Storage after reconstitution: 2-8°C for up to 14 days.
• Extended storage: Aliquot and freeze at -20°C for up to 3 months.

Compliance and Intended Use

Research Use Only (RUO). Semaglutide as supplied by Wholesale Bulk Peptides is intended solely for in vitro research and preclinical studies conducted by qualified researchers. This product is not intended for human or veterinary diagnostic or therapeutic use. It is not a drug, food additive, or cosmetic ingredient.

Semaglutide has been approved by the FDA under various brand names for specific clinical indications when manufactured under cGMP by licensed pharmaceutical companies. The research-grade material supplied by Wholesale Bulk Peptides is distinct from these pharmaceutical products and is not intended as a substitute for FDA-approved medications.

Purchasers assume responsibility for compliance with all applicable regulations governing research peptide use.

Related Compounds

• Tirzepatide — A dual GLP-1/GIP receptor agonist representing the next evolution in incretin-based research.
• Retatrutide — A triple agonist (GLP-1/GIP/glucagon) under investigation as a next-generation metabolic research compound.
• NAD+ — A coenzyme studied in metabolic research for its role in energy metabolism and cellular function.

References

1. Lau J, Bloch P, Schaffer L, et al. Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. J Med Chem. 2015;58(18):7370-7380. PMID: 25648656
2. Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834-1844. PMID: 27633186
3. Blundell J, Finlayson G, Axelsen M, et al. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight. Diabetes Obes Metab. 2017;19(9):1242-1251. PMID: 28655529
4. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002. PMID: 33567185
5. Newsome PN, Buchholtz K, Cusi K, et al. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N Engl J Med. 2021;384(12):1113-1124. PMID: 33185364

Frequently Asked Questions

What is semaglutide?

Semaglutide is a long-acting glucagon-like peptide-1 receptor agonist (GLP-1 RA) and a structural analog of human GLP-1(7-37). It incorporates an Aib substitution at position 8 for DPP-4 resistance and a C18 fatty diacid side chain at Lys26 for albumin binding, resulting in an extended half-life of approximately 165 hours.

How does research-grade semaglutide differ from branded pharmaceutical products?

Research-grade semaglutide supplied by Wholesale Bulk Peptides is manufactured for in vitro and preclinical research use only. It is chemically equivalent in its peptide sequence and modifications but is not manufactured under pharmaceutical cGMP conditions and is not intended as a substitute for FDA-approved products.

What is the purity of your semaglutide?

All semaglutide is supplied at 99% or greater purity verified by reverse-phase HPLC, with additional MS, amino acid analysis, and endotoxin testing. Fatty acid conjugation is verified by LC-MS. Batch-specific COAs document all analytical results.

How should semaglutide be stored?

Lyophilized semaglutide should be stored at -20 degrees Celsius for long-term stability. Reconstituted solutions should be stored at 2-8 degrees Celsius and used within 14 days, or aliquoted and frozen at -20 degrees Celsius for up to 3 months.

What is the minimum order quantity?

Wholesale semaglutide orders start at a minimum of 10 vials. Volume discounts begin at 50 vials with savings up to 45% for orders of 500-999 vials. Custom pricing is available for orders exceeding 1,000 vials.

What reconstitution vehicle is recommended?

Bacteriostatic water or sterile phosphate-buffered saline (PBS, pH 7.4) are the most commonly used vehicles. Semaglutide is soluble in aqueous solutions, though the fatty acid modification may require brief vortexing for complete dissolution.

Is research-grade semaglutide approved for human use?

No. Research-grade semaglutide from Wholesale Bulk Peptides is classified as Research Use Only (RUO) and is not approved for human or veterinary use. FDA-approved semaglutide products are manufactured by licensed pharmaceutical companies under cGMP.

What research applications use semaglutide?

Semaglutide is used in metabolic, obesity, diabetes, cardiovascular, neuroscience, and hepatic research. It serves as a reference standard in GLP-1 receptor agonist research and is used in comparative studies with newer incretin analogs.

How does semaglutide compare to tirzepatide?

Semaglutide is a selective GLP-1 receptor agonist, while tirzepatide is a dual GLP-1/GIP receptor agonist. Both are studied in metabolic research, with tirzepatide representing a newer dual-agonist approach. Comparative studies examining their respective efficacy profiles are an active area of investigation.

What documentation is provided?

Every semaglutide order includes a batch-specific Certificate of Analysis documenting HPLC purity, MS identity, amino acid analysis, endotoxin levels, fatty acid conjugation verification, and appearance data. Safety Data Sheets are available upon request.

What is the lead time?

Standard wholesale orders ship within 3-5 business days. Bulk powder orders may require 7-10 business days for preparation. Expedited processing is available for time-sensitive research programs.

Can semaglutide be used in combination studies?

Yes. Semaglutide is frequently used in comparative and combination studies with other metabolic research compounds including tirzepatide, retatrutide, and various metabolic pathway modulators. Researchers should verify peptide compatibility in solution before combining.